These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36432436)

  • 21. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Adherence to the Mediterranean Diet and Level of Physical Activity with Liver Steatosis in People Aged > 50 Years and with a BMI > 25 kg/m
    Cano-Lallave L; Ruiz-Tovar J; Martin-de-Bernardo L; Martinez-Oribe M; Rodriguez-Obispo C; Carrascosa-Corrochano S; Martín-Nieto A; Baeza I; Gonzalez-Ramos M; Benito M; Olazabal I
    Nutrients; 2024 Jun; 16(13):. PubMed ID: 38999744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.
    Fennoun H; Mansouri SE; Tahiri M; Haraj NE; Aziz SE; Hadad F; Hliwa W; Badr W; Chadli A
    Pan Afr Med J; 2020; 37():270. PubMed ID: 33598084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid dysfunction and hepatic steatosis in overweight children and adolescents.
    Kaltenbach TE; Graeter T; Oeztuerk S; Holzner D; Kratzer W; Wabitsch M; Denzer C
    Pediatr Obes; 2017 Feb; 12(1):67-74. PubMed ID: 26877190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.
    Sangineto M; Bukke VN; Bellanti F; Tamborra R; Moola A; Duda L; Villani R; Romano AD; Serviddio G
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33671262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity.
    Kashiwagi K; Takayama M; Fukuhara K; Shimizu-Hirota R; Chu PS; Nakamoto N; Inoue N; Iwao Y; Kanai T
    Clin Nutr ESPEN; 2020 Aug; 38():86-93. PubMed ID: 32690183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors.
    Thiagarajan S; Shrinuvasan S; Arun Babu T
    Indian J Gastroenterol; 2022 Feb; 41(1):63-68. PubMed ID: 35064452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study.
    Sorrentino G; Crispino P; Coppola D; De Stefano G
    Drugs R D; 2015 Mar; 15(1):21-5. PubMed ID: 25732561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.
    Guo W; Qin P; Li XN; Wu J; Lu J; Zhu WF; Diao QQ; Xu NZ; Zhang Q
    Front Endocrinol (Lausanne); 2021; 12():711956. PubMed ID: 34456869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between Dietary Fatty Acid Intake and Liver Steatosis and Fibrosis in a Sample of Mexican-Origin Hispanic Adults with Overweight or Obesity.
    Lopez-Pentecost M; Hallmark B; Thomson CA; Chilton F; Garcia DO
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
    Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
    Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern.
    Nier A; Brandt A; Conzelmann IB; Özel Y; Bergheim I
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30235828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial.
    Marin-Alejandre BA; Abete I; Cantero I; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Quiroga J; Martinez-Echeverria A; Uriz-Otano JI; Huarte-Muniesa MP; Tur JA; Martinez JA; Zulet MA
    Nutrients; 2019 Oct; 11(10):. PubMed ID: 31652512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
    Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
    World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediterranean-Oriented Dietary Intervention Is Effective to Reduce Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: Results from an Italian Clinical Trial.
    Zanini B; Benini F; Marullo M; Simonetto A; Rossi A; Cavagnoli P; Bonalumi A; Marconi S; Pigozzi MG; Gilioli G; Valerio A; Donato F; Castellano M; Ricci C
    Int J Clin Pract; 2024; 2024():8861126. PubMed ID: 38303926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.